PAR-25-442 Undruggable Targets R21 Guide
Updated 6 official sources
Quick Answer: PAR-25-442 undruggable targets R21 eligibility in 2026 turns on 6 checks: hard target class, human disease relevance, selective method or agent, preclinical proof endpoint, no clinical trial, and 2-year R21 scope.
Full answer and how we checked it
PAR-25-442 undruggable targets R21 eligibility in 2026 turns on 6 checks: hard target class, human disease relevance, selective method or agent, preclinical proof endpoint, no clinical trial, and 2-year R21 scope.
Who this is for: Translational science teams, NCATS-aligned researchers, rare-disease teams, assay groups, molecular biology labs, medicinal chemistry collaborators, and sponsored-research offices deciding whether an R21 is the right route for a hard target class.
Data note: This guide uses NIH PAR-25-442 (opens in a new tab), NICHD notice NOT-HD-25-028 (opens in a new tab), NIH R21 parent guidance (opens in a new tab), NIH clinical trials policy (opens in a new tab), Grants.gov listing 359154 (opens in a new tab), and Grantsights award-data signals checked on June 19, 2026.
In this guide
- Source Check
- 6 PAR-25-442 Eligibility Stop Checks
- 5 Funding, Timing, and Mechanism Rules
- 5 Route Choices Before Drafting
- What NIH Doesn't Tell You
- 7 Evidence Assets That Make This R21 Stronger
- 7 Source-Backed Search Questions
- 21-Day R21 Routing Plan
- 6 Reviewer-Risk Signals to Fix
- 5 Applicant Types and Best Next Move
- 8 Applicant Memo Lines to Include
- Sources
| First-screen check | PAR-25-442 answer |
|---|---|
| Mechanism | NIH R21 |
| Trial status | Clinical trial not allowed |
| Budget | $275,000 direct costs over 2 years |
| Core fit | Hard target class and preclinical proof |
| Bad fit | Standard target, clinical work, or product-scale program |
PAR-25-442 is not a broad drug discovery R21. According to NIH PAR-25-442 (opens in a new tab), applicants should identify a human-disease-relevant target class that cannot be engaged well by conventional approaches and develop a method or agent that can act selectively on one or more targets in that class.
Some R21 ideas are exciting but the fit is thin. The common failure is treating "difficult target" as enough. This route asks for a harder claim: the target class must be hard for current modalities, tied to intractable disease, and ready for preclinical proof.
Use this guide with the live NIH Undruggable Targets R21 program record. Then compare NIH grants complete guide, NIH R01 R21 R03 K awards comparison, what is a NOFO, NEI Vision Secondary Data R21 guide, and the Grantsights grant database.
Source Check
Checked June 2026.
As of June 19, 2026, PAR-25-442 remains the NIH R21 route for exploratory and early-stage work on hard target classes in intractable human disease, with clinical trials not allowed. The May 15, 2026 new-application date has passed, so the next practical planning window is February 17, 2027 unless NIH changes the NOFO. NIH added NICHD participation through NOT-HD-25-028, which matters for child health and developmental disease projects.
The first screen should not sell this as a broad drug-discovery route. It should screen for a truly hard target class, a human-disease link, selective method or agent proof, preclinical endpoint, R21 budget fit, institute fit, and a clear next route after the 2-year award.
| Current source owner | What the applicant should do |
|---|---|
| NIH PAR-25-442 | Confirm February 17, 2027 timing, February 17, 2028 later listed date, clinical-trial-not-allowed status, and target-class scope |
| NOT-HD-25-028 | Check NICHD fit for child health, developmental disease, and related projects |
| NIH R21 guidance | Keep the proof plan inside the $275,000 and 2-year R21 frame |
| NIH clinical-trial policy | Stop if the project assigns people to an intervention to test a health outcome |
Get grant deadline alerts by email
About once a week, we email a short list of open grant calls with real deadlines from different funders. It isn't limited to the programs in this guide.
No spam. Unsubscribe anytime.
6 PAR-25-442 Eligibility Stop Checks
6 stop checks decide whether this R21 fits. The project should be exploratory, preclinical, disease-relevant, and centered on a target class that current methods cannot handle well.
| Stop check | Strong R21 signal | Red flag |
|---|---|---|
| Target class | Conventional methods do not engage it well | Ordinary receptor, enzyme, or transporter work |
| Disease link | Human disease relevance is direct | Target is interesting but disease path is vague |
| Method or agent | Selective method or agent can be tested | Discovery aim has no proof endpoint |
| Trial status | No NIH-defined clinical trial | Human intervention assignment is planned |
| Scope | 2-year R21 proof is plausible | Full R01 or product program is hidden inside |
| Next step | Result can support larger technology or route choice | No clear post-R21 decision |
Don't use this R21 as a label for any difficult biology. Use it when the central scientific question is whether a hard target class can be modulated with a credible preclinical method.
5 Funding, Timing, and Mechanism Rules
5 public rules should appear before the aims page. According to NIH, PAR-25-442 is an R21 exploratory/developmental grant and clinical trials are not allowed. The next listed planning date is February 17, 2027, with February 17, 2028 also listed later in the NOFO cycle.
| Rule | Source-backed read |
|---|---|
| Funding number | PAR-25-442 |
| Mechanism | R21 exploratory/developmental research grant |
| Clinical trial status | Not allowed |
| Budget | Up to $275,000 direct costs over 2 years, no more than $200,000 in one year |
| Next listed due date | February 17, 2027 |
| Later listed due date | February 17, 2028 |
According to USAspending.gov (opens in a new tab) data, assistance listing 93.350 had about $588.2M in FY2024 obligations across 731 awards active that year. That market signal matters, but it does not replace source fit. The proposal still has to show why the target class is outside ordinary drug discovery.
According to NIH R21 guidance, exploratory/developmental grants are meant for early-stage research where a limited period and budget can answer a focused question. According to NIH clinical trials policy, PAR-25-442 does not allow clinical trials, so human-intervention work needs a different route.
5 Route Choices Before Drafting
5 route choices matter because teams often pick this R21 when another route is cleaner.
| Route | Better first read when... | Why |
|---|---|---|
| PAR-25-442 R21 | Hard target class needs preclinical proof | R21 scope fits |
| Parent R21 | Biology is early but not tied to this target-class rule | Broader route may fit |
| Parent R01 | Preliminary evidence already supports larger aims | R01 scale may fit |
| NCI cancer route | Most of the work focuses on cancer | PAR-25-442 won't review cancer-majority projects |
| SBIR/STTR | Company-led product work is central | Small-business route may fit |
The best first move is a 1-page fit memo. If that memo cannot define the target class, why ordinary methods fail, what method or agent will be tested, and what proof will be produced, the team should pause.
What NIH Doesn't Tell You
4 hidden readiness questions decide whether PAR-25-442 is worth pursuing. NIH gives the rules, but review will test the logic behind the target and proof plan.
First, NIH does not make a target hard just because it has been slow to yield drugs. The application should explain what makes the target class poorly suited to current approaches.
Second, NIH does not make preclinical proof easy. The R21 should still define selectivity, assay quality, disease relevance, and a credible proof endpoint.
Third, NIH does not allow clinical trials here. If the project assigns an intervention to human participants to evaluate a health outcome, this route is wrong.
Fourth, NIH does not guarantee institute fit. NCATS, NEI, NIAID, NIDCR, NIMH, and NICHD participation signals different disease and translational interests. The applicant should name the best institute fit before submission.
Based on our analysis of indexed NIH mechanism guides, the practical gap for PAR-25-442 is that the official NOFO describes hard target classes, but it does not score whether the applicant's target is truly outside ordinary target-based approaches. Grantsights analysis of award data and route evidence says applicants should apply only when the target class, disease link, selective method, assay proof, and next-route decision all fit inside R21 scope. If the target is a familiar receptor, enzyme, transporter, or pathway with standard assays, this is probably a bad fit even if the biology is difficult.
7 Evidence Assets That Make This R21 Stronger
7 evidence assets make the R21 easier to defend. The strongest applications prove target-class fit and R21 scope together.
First, define the target class in plain terms. Intrinsically disordered proteins, RNA, organelles, metabolites, or other hard entities can fit only when the application explains why the class is hard to engage.
Second, tie the target class to intractable human disease. The disease link should not be a future hope. It should explain why modulating this class matters.
Third, show method selectivity. A method or agent that broadly perturbs a pathway may not satisfy the route if it does not act selectively enough.
Fourth, define the preclinical proof endpoint. For example, a university team studying RNA structural states in a rare neurologic disease could define target engagement, assay reproducibility, and downstream disease-model readout before the R21 starts.
Fifth, handle off-target and artifact risk. Hard target classes are often measured with fragile assays. Orthogonal methods, counterscreens, and reproducibility checks matter.
Sixth, explain why R21 scope is enough. If the project needs full medicinal chemistry, animal efficacy, formulation, and toxicology, it is not really an R21.
Seventh, state the next route. The R21 should decide whether the team moves to R01, SBIR/STTR, translational development, or stops.
7 Source-Backed Search Questions
7 search questions should be answered on the public page because they match how applicants evaluate this route. The first is whether PAR-25-442 is truly for hard target classes. The answer is yes, but the applicant should not assume that every hard project qualifies.
The second question is whether the route is clinical. It isn't. The application should stay preclinical and should not assign human participants to an intervention.
The third question is whether cancer-primary work fits. It doesn't. PAR-25-442 (opens in a new tab) lists projects where the majority of the proposed work focuses on cancer as non-responsive, and those applications won't be reviewed or considered for funding. If cancer is the main setting, use an NCI route instead.
The fourth question is whether an R21 is enough. The R21 is strongest when it can produce proof of selective modulation, assay validity, or a method signal without pretending to finish a product.
The fifth question is what budget reality applies. The $275,000 direct-cost cap over 2 years means the work plan must be tight.
The sixth question is whether NICHD now participates. NIH notice NOT-HD-25-028 says NICHD participation was added, which matters for child health and developmental disease teams.
The seventh question is what happens after the R21.
21-Day R21 Routing Plan
21 days is enough to decide whether the team should draft. Days 1 through 3 should confirm PAR-25-442 status, deadline, participating institute fit, trial status, and budget scope.
Days 4 through 7 should define the target class and the disease link. The team should be able to explain why ordinary approaches are not enough.
Days 8 through 12 should build the proof table: method or agent, selectivity, assay, model, endpoint, and failure threshold.
Days 13 through 16 should compare routes. If most of the work focuses on cancer, move to an NCI route, since this R21 won't review it. If company translation is central, compare SBIR/STTR. If the work is broader, compare parent R21 or R01.
Days 17 through 21 should build the submission memo, including clinical-trial status, institute fit, budget, biosafety, data sharing, and program-staff questions.
6 Reviewer-Risk Signals to Fix
6 risk signals should be fixed before submission. First, the proposal should not rely on the phrase hard target without explaining mechanism.
Second, the proof endpoint should not be vague. Reviewers need to know what success means.
Third, the target class should not be conventional. Ordinary enzyme or receptor work may not fit.
Fourth, the project should not hide clinical work inside preclinical language.
Fifth, the work should not be a full product-development program squeezed into R21 scope.
Sixth, the next-step logic should be visible. The R21 should produce a clear go, no-go, or route-change decision.
5 Applicant Types and Best Next Move
5 applicant types commonly ask about PAR-25-442.
| Applicant type | Best next move | Why |
|---|---|---|
| Translational biology team | Define target-class proof table | Route may fit |
| Standard drug-target team | Compare parent NIH routes | Target may not fit |
| Cancer-primary team | Use an NCI cancer route | Cancer-majority projects are non-responsive |
| Company-led team | Compare SBIR/STTR | Product path may fit better |
| Sponsored-project office | Check budget and trial status | Technical fit can block |
The best answer is: use PAR-25-442 when the target class is truly hard for current methods, the project is preclinical, and the R21 can produce clear proof for the next route.
The final test is simple: if the aims can't explain target-class difficulty, selective modulation, disease relevance, and a 2-year proof endpoint in one page, don't draft yet.
8 Applicant Memo Lines to Include
8 memo lines help a team decide whether this is a serious PAR-25-442 candidate. According to NIH, the R21 budget is capped at $275,000 in direct costs over 2 years, so each memo line should support a narrow work plan. Line 1 should name the target class and explain why conventional approaches are weak.
Line 2 should name the disease and why the disease remains hard to treat, relieve, or cure with current options.
Line 3 should describe the method or agent that will be tested and why selectivity can be judged inside 2 years.
Line 4 should define the assay, model, or readout that proves modulation rather than only association.
Line 5 should name the participating NIH institute that best matches the disease area.
Line 6 should state why the work is not a clinical trial.
Line 7 should show the budget can fit inside the R21 cap without hiding product-development work.
Line 8 should name the next route. If the memo can't say whether success leads to R01, SBIR/STTR, NCATS translation, or a stop decision, the project isn't ready.
Sources
3 sources anchor this guide: the NIH R21 NOFO, the NICHD participation notice, and the Grantsights public database record.
- NIH PAR-25-442 R21 NOFO: grants.nih.gov (opens in a new tab)
- NIH NOT-HD-25-028 participation notice: grants.nih.gov (opens in a new tab)
- NIH R21 parent guidance: grants.nih.gov (opens in a new tab)
- NIH clinical trials policy: grants.nih.gov (opens in a new tab)
- Grants.gov listing 359154: grants.gov (opens in a new tab)
- Grantsights grant database: Search NIH target-discovery routes
Next steps
Where to go next
These next pages help you move from research into a specific grant choice.
Open the R21 record
Check PAR-25-442, hard target class fit, no-trial status, budget cap, and source links.
Compare mechanisms
Use when the project may need parent R21, R01, or another NIH route.
Compare NCI assays
Use when assay development or hit validation is stronger than target-class proof.
Compare cancer tech
Use when cancer nanotechnology or NCI translational routes fit better than PAR-25-442.
Find grants that fit you
Free eligibility check: answer 9 questions and see ranked matches with deadlines and fit reasons.
Frequently Asked Questions
What does PAR-25-442 fund?
NIH says the R21 supports exploratory and early-stage projects focused on undruggable target classes in intractable human disease.
Are clinical trials allowed?
No. PAR-25-442 is clinical trial not allowed.
What budget should applicants expect?
NIH R21 rules for this route allow up to $275,000 in direct costs over 2 years, with no more than $200,000 in any single year.
Who should skip this route?
Skip it if the project is a standard druggable target, a clinical trial, or a project where most of the work focuses on cancer. NIH treats those cancer-majority applications as non-responsive and won't review them.
What is the strongest first check?
Confirm the target class is truly outside conventional targeting methods and that the project can show preclinical proof within R21 scope.
Last updated October 10, 2026. Corrected October 10, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
PAR-25-369 ELSI R21 eligibility Guide
PAR 25 369 ELSI R21 guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.
maternal pediatric pharmacology R21 eligibility Guide
PAR 25 111 maternal pediatric guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.
PAR-25-357 NEI Secondary Data R21 Eligibility Guide
NIH PAR-25-357 guide: NEI secondary-data R21 eligibility, clinical-trial-not-allowed fit, data readiness, manuscript milestones, and review checks.
PAR-25-266 newborn screening R21 eligibility Guide
PAR 25 266 newborn screening guide: 7 checks for eligibility, source status, budget, evidence, route fit, review criteria, and team readiness in 2026.
PA-25-304: NIH Parent R21 (Clinical Trial Not Allowed)
PA-25-304 is NIH's parent R21 with no clinical trial: $275,000 over 2 years, 21 institutes. Next due Nov 16, 2026 and Feb 16, 2027; expires Jan 8, 2028.
RFA-TR-25-002 Rare Disease R21 Eligibility Guide
RFA-TR-25-002 rare disease preclinical R21 guide: June 2, 2027 deadline, clinical-trial status, budget caps, model-readiness checks, and bad-fit rules.